Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00929578Phase 2Completed

Fluphenazine Hydrochloride for Psoriasis

Role: collaborator

NCT00335647Phase 1Completed

Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma

Role: lead

NCT00356200Phase 2Terminated

Fluphenazine Decanoate for Psoriasis

Role: collaborator

NCT00821301Phase 1Unknown

Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Role: lead

All 4 trials loaded